The roleof lifestyle modification in HF is the most well-established treatment option;improvements in exercise capacity, as measured by VO2, have been reported inpatients with HFpEF following caloric restriction and aerobic exercise [30].Glucagon like peptide-1 (GLP-1) receptor agonists have also emerged as apromising pharmacological option for weight management in HF patients. This evidence concerns the gene GCG and hydrops fetalis.